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Heterogeneous populations of human bone marrow-derived stromal cells (BMSC) are
among the most frequently tested cellular therapeutics for treating degenerative and
immune disorders, which occur predominantly in the aging population. Currently, it is
unclear whether advanced donor age and commonly associated comorbidities affect
the properties of ex vivo-expanded BMSCs. Thus, we stratified cells from adult and
elderly donors from our biobank (n = 10 and n = 13, mean age 38 and 72 years,
respectively) and compared their phenotypic and functional performance, using multiple
assays typically employed as minimal criteria for defining multipotent mesenchymal
stromal cells (MSCs). We found that BMSCs from both cohorts meet the standard criteria
for MSC, exhibiting similar morphology, growth kinetics, gene expression profiles, and
pro-angiogenic and immunosuppressive potential and the capacity to differentiate toward
adipogenic, chondrogenic, and osteogenic lineages. We found no substantial differences
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between cells from the adult and elderly cohorts. As positive controls, we studied the
impact of in vitro aging and inflammatory cytokine stimulation. Both conditions clearly
affected the cellular properties, independent of donor age. We conclude that in vitro
aging rather than in vivo donor aging influences BMSC characteristics.
Keywords: cellular therapy, bone marrow stromal cell, mesenchymal stromal cell, in vivo and in vitro aging,
comorbidity, in vitro potency assay
GRAPHICAL ABSTRACT | Overview on the molecular and functional assays used for the characterization of biobanked bone marrow stromal cells (BMSC) with
respect to in vivo and in vitro aging, with primary assessment of starting material composition, cell morphology, immunophenotype, gene expression profile,
multilineage differentiation capacity, immunomodulation, endothelial tube formation and inflammatory response.
INTRODUCTION
Qualifying adult regenerative cell sources in biobanking
approaches is an essential task in order to overcome major
pitfalls in regenerative medicine (1). Donor-intrinsic variation
between different cell batches may influence the safety and
efficacy of bone-marrow stromal cells (BMSCs) (2–4). Our
previous work suggests that multiple parameters, such as tissue
origin (5–7), culture time (8, 9), media supplementation (7, 10),
and mode of cell delivery (4, 9, 11–13) can substantially affect
cellular therapeutic properties. In addition, advanced donor age
and the commonly associated comorbidities are thought to be
another substantial confounder of potentially compromising
BMSC phenotype and function (14–22).
Previous studies investigating the impact of donor age
on BMSCs reported variable or partly inconclusive outcomes
considering their in vivo frequency, their gene expression
profile, and many of their functional parameters, such as
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antioxidant defense, cytoskeleton dynamics, migration behavior,
differentiation capacity, and immunomodulatory and paracrine
activity (Table 1) (14–22). These discrepancies may result from
differences in experimental parameters such as donor species,
cell isolation, and culture protocols and from small sample size
or limited functional characterization. Potential age-dependent
impairments by chronological in vivo aging may be further
aggravated by the process of in vitro aging during serial expansion
in tissue culture (14, 16). Thus, the true impact of advanced donor
age on the therapeutic value of BMSCs is still rather unclear.
We hypothesized that donor age, in combination with
age-related comorbidities, contributes to the perceived large
phenotypic and functional heterogeneity between individual
donor-derived cellular specimens. Surprisingly, we found no
substantial association between donor age or comorbidities and
BMSC characteristics. In contrast, our analysis revealed that in
vitro aging and inflammatory cytokine stimulation clearly alter
cellular properties.
MATERIALS AND METHODS
Isolation and Culture of Bone Marrow
Stromal Cells (BMSCs)
BMSCs were received from the Core-Facility “Cell Harvesting”
of the BIH Center for Regenerative Therapies (BCRT). The cells
were isolated from metaphyseal bone marrow (BM) biopsies
from patients undergoing hip replacement at Charité University
Hospital, as previously stated (1, 66–68). Written informed
consent was given, and ethics approval was obtained from the
local ethics committee/institutional review board (IRB) of the
Charité University Hospital.
Briefly, the BM mononuclear cell fraction (BM-MNC)
in primary BM and the BMSC fraction post Ficoll-density
gradient centrifugation (Histopaque 1077; Sigma-Aldrich)
were quantified with an automated electrical impedance-based
CASY R© Cell Counter (Schaerfe System GmbH). The BMSC-
containing interphase was plated in a 300 cm2 tissue culture flask
(ThermoFischer) and cultured under standard conditions (37◦C,
5% CO2) in an expansion medium (Dulbecco’s Modified Eagle
Medium-Low Glucose [DMEM-LG; Sigma-Aldrich] containing
10% fetal calf serum [FCS; Biochrom AG], 100 U/mL penicillin,
and 100µg/mL streptomycin [Biochrom AG], and 2mM
L-alanyl-L-glutamine [GlutaMAX; Gibco]). The non-adherent
fraction was removed by washing with PBS (Gibco), the medium
was changed every 72 h, and the cells were allowed to reach about
80% confluence before passaging.
The BMSCs were then expanded for several passages and were
characterized with multiple functional and molecular assays, in
line with the minimal criteria of the International Society for
Cellular Therapy (ISCT) (69), at passage three (P3, early passage)
and six (P6, late passage), respectively, as also shown in overview
in the Graphical Abstract.
Cell Morphology, Viability, Growth Kinetics,
and Immunophenotyping
Cell morphology was determined at regular intervals by using
bright field light microscopy. Cell number, viability, size, and
volume were determined at each culture passage by using the
CASY R© Cell Counter as outlined previously (6, 9). BMSC growth
kinetics were quantified by calculating population doublings
at each passage based on the following equation: PD =
log(N/N0)/log(2). In this formula, N stands for the total number
of viable cells at harvest, and N0 is the initial number of
cells seeded.
Flow cytometric immunophenotyping was conducted
as described earlier (6, 9) using a BMSC Duraclone-panel
(DURAClone SC Mesenchymal Tube; Beckman Coulter)
containing the following antibodies: CD14, CD19, CD31, CD34,
and CD45 (as negative markers) and CD73, CD90, CD105,
and CD146 (as positive markers), or unlabeled control cells.
Upon antibody labeling, the cells were washed with PBS, fixed
with 1% paraformaldehyde, and analyzed on a Cytoflex flow
cytometer (Beckman Coulter), and 5,000–10,000 gated events
were quantified and analyzed with FlowJo v10.3.1 (FlowJo LLC).
Gene Expression Analysis by RNA
Sequencing
The mRNA transcripts of resting or cytokine-stimulated BMSCs
were studied by seeding the cells at 2,000–4,000 cells/cm2 in
75 cm2 culture flasks and expanding them for 1 week. Before
harvest, the sub-confluent cells were washed twice with PBS and
lysed with 1mL of RLT-buffer (Qiagen). Total RNAwas extracted
by using the Qiagen RNeasy Plus Mini Kit (Qiagen), according
to the manufacturer’s instructions. A total of n = 37 BMSC
samples were analyzed (n = 24 samples for P3 and n = 6 for
P6, which were matched to n = 6 of the P3 donors). A subset
of n = 7 donors was treated for 24 h with or without cytokines
(TNF-alpha and IFN-gamma, both 10 ng/mL), which were
matched to the corresponding unstimulated cells and processed
in parallel.
Total RNA was extracted by using the RNeasy Plus Mini Kit,
and the quality was assessed by Bioanalyzer RNA 6000 Nano
assay (Agilent). Only high-quality RNA with RIN scores > 7 was
used for library preparations. The RNA (1 µg of total RNA) from
each sample was converted to complementary DNA (cDNA)
using an iScriptTM cDNA Synthesis Kit (Bio-Rad). Sequencing
library preparation was performed using the NEBNext R© UltraTM
RNA Library Prep Kit for Illumina R© and PolyA mRNA selected
from 500 ng of total RNA with a NEBNextPoly(A) mRNA
Magnetic IsolationModule (both New England Biolabs) followed
by library preparation. Libraries were quantified with a Qubit R©
dsDNA HS Assay Kit (Thermo Fischer) and sequenced on a
HiSeq 4000 System (Illumina) in single-read mode with a 50-
cycle read length.
FASTQ-files were quality-controlled with “fastQC” and
trimmed for residual adapter sequences and low-quality reads
with “AdapterRemoval” (70). Reads were aligned to the GRCh38
human genome using “tophat” and “bowtie2” (71, 72). Counts
per gene were calculated using the “featureCounts” algorithm
implemented in the “Rsubread” package in R (73). Genes
were annotated with the “biomaRt” package and Ensembl-
Version 94. Protein-coding genes were selected, expression
values normalized, and variance stabilizing transformed using the
“DESeq2” package in R (74). Principle component analysis (PCA)
was performed for the 1,000 genes with the highest variance
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Age range (Years) Passage
number
Parameters changed by aging and/or comorbidity Ref.
BMSCs In vivo Human;
Healthy individuals;
N=8
16–32, 69–77 N.A. (–) Proliferation
(–) Immunophenotype
(–) Metabolic activity
(–) Trophic factor secretion
Therapeutic efficacy in C57/BL6 mouse model
↓ Wound healing
↓ Neovascularization
↓ Trophic factor secretion

























≤23, ≥65 P1–P2 ↓ CFU-F
↑ Senescence
↑ Cell size




BMSCs In vivo Human;
Patients with hip OA;
N = 19
















BMSCs In vivo Human;
Healthy individuals;
N = 30





BMSCs In vivo Human;
Healthy individuals;
N = 33










BMSCs In vivo Human;
Healthy individuals;
N = 36
41–86 ↓ Proliferation (30)
BMSCs In vivo Healthy individuals;
N = 41
3–70 N.A. ↓ Number of osteoprogenitors (31)
BMSCs In vivo Human;
Healthy individuals;
N = 46
≥18 P1–P3 (–) Cell number/sample weight
(–) Immunophenotype
(–) Proliferation
(–) Osteogenic, adipogenic, chondrogenic potential
(32)
BMSCs In vivo Human Healthy
individuals;
N = 53
13–80 P1 Altered immunophenotype,
(–) Proliferation
(–) Adipogenic, osteogenic, chondrogenic potential
(–) Immunomodulatory activity
(–) Trophic factor secretion
(33)
(Continued)
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Age range (Years) Passage
number
Parameters changed by aging and/or comorbidity Ref.









BMSCs In vitro Human;
Healthy individuals;
N = 3
N.A. P4, P8, P12 ↓ Proliferation
↓ Immunomodulatory activity
(–) Immunophenotype, telomere length
(–) Metabolic activity
(35)
BMSCs In vitro Human;
Healthy individuals;
N = 6






BMSCs In vitro Human;
Healthy individuals;
N = 11













(–) Adipogenic and osteogenic potential
(38)




















N.A. ↓ Osteogenic potential
↑ Adipogenic potential
(41)
BMSCs In vivo Mouse; (SAMP6,
SAMR1); N.A.
3 to 5-month-old N.A. ↓ Osteogenic potential
↑ Adipogenic potential
(42)
BMSCs In vivo Mouse;
(C57BL/6); N.A.
4 to 5-month-old 22
to 25-month-old





























(–) Immunophenotype (except CD73)


















N.A. Altered immunophenotype (CD29, CD90, CD11, CD45) (46)
BMSCs In vivo Rat; (Wistar); N.A. 12-month-old 24-
month-old
N.A. ↓ Osteogenic potential (47)
(Continued)
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Age range (Years) Passage
number




















AT-MSCs In vitro Human;
Healthy individuals;
N = 3
N.A. P5, P10, P15 ↓ Proliferation
↑ Cell size
↑ Morphological heterogeneity
(–) Osteogenic, adipogenic, chondrogenic potential
(–) Immunophenotype (except CD105)
(49)
AT-MSCs In vivo Human;
Healthy individuals;
N = 8




















AT-MSCs In vivo Human;
Patients with CAD &
healthy individuals;
N = 95




AT-MSCs In vivo Human;
Healthy individuals;
N = 260
5–97 P0, P5 ↓ Adipogenic potential
(–) CFU-F
(–) Proliferation
(–) Osteogenic and chondrogenic potential
(53)
UC-MSCs In vitro Human;
Healthy
individuals; N.A.
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number
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Age range (Years) Passage
number
Parameters changed by comorbidity Ref.
AT-MSCs T2D with CLI Human; T2D
Patients; N.A.













N.A. N.A. Altered immunophenotype (CD90, CD105)
↑ Expression of stemness markers (NANOG, OCT4)
↑ Oxidative stress
























Patients with Obesity &
T2D
N = 12
30–55 P3–P7 ↓ Immunomodulatory activity
↑ Metabolic activity
↑ Migration potential
↑ Expression of inflammatory markers
(63)
BM-ECs T1D Mouse; T1D and
non-diabetic
(CD1); N.A.





BM-ECs T1D Mouse; T1D and
non-diabetic
(CD1); N.A.
N.A. N.A. ↓ Hematopoietic fraction in bone
↓ Migration
↓ Angiogenic potential
↑ Osteopenia in bone




N.A., not available; Cell types: BMSCs, bone marrow stromal cells; MSC, mesenchymal stromal cells; Tissue sources: AT, adipose tissue; BM, bone marrow; UC, umbilical cord;
P, passage number; Parameters: PD, population doubling; CFU-F, colony-forming unit fibroblast; SASP, senescence-associated secretory phenotype; PDGF, platelet-derived growth
factor; Comorbidities: CLI, critical limb ischemia; T1D/T2D, type 1 and 2 diabetes mellitus; ATH, atherosclerosis; CAD, coronary artery disease; OA, osteoarthritis.
across all samples. Differentially expressed genes between groups
were determined using negative binomial distribution models
as implemented in the “DESeq2” package. Raw p-values were
adjusted for multiple testing with Bonferoni correction, and
an adjusted p-value below 0.05 was used for the selection of
significant genes. Functional annotation and enrichment analysis
were carried out using “DAVID” with the “clusterProfiler”
package in R (75). False discovery rates were used to adjust
raw p-values for multiple testing, and a threshold of p < 0.05
was used for the selection of significant results. Dotplots of top-
ranking results were created with the function implemented in
the “clusterProfiler” package. GOcirc plots were created using the
algorithm in the “GOplot” package in R (76). The raw data on
expression are available at the Gene Expression Omnibus under
the GEO-Accession-ID (GSE139073).
Multilineage Differentiation Analysis
Adipogenic, osteogenic, and chondrogenic differentiation
of BMSCs at P3 and P6 were induced by using specific
differentiation media and evaluated as previously described
(48, 66–68, 77–79). Briefly, BMSCs were plated in 24-
well plates at specific densities for adipogenic (1.44 × 104
cells/well) or osteogenic (1.28 × 104 cells/well) differentiation
or in V-bottom 96-well plates at higher density (3.0 ×
105 cells/well) for chondrogenic differentiation. Control
cells were exposed to normal culture media, and all
cultures were sustained for up to 22 days. To compare the
differentiation potential of BMSCs among age groups and
comorbidities and between passages, the differentiation
responses from each individual were normalized to their
respective controls.
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Adipogenic Induction
BMSCs were cultured with complete DMEM-HG (High
Glucose) supplemented with 10µM dexamethasone, 50µM
indomethacin, 10mM 3-isobutyl-1-methylxanthine, and 0.1µM
insulin (all from Sigma-Aldrich, St. Louis, MI, USA). Adipogenic
differentiation was demonstrated by performing Nile Red
staining (Sigma-Aldrich) to visualize lipid droplet formation.
Quantification was achieved by measurement of Nile Red
fluorescence (Ex/Em 485/540), which was normalized to the
cell number quantified by staining with Hoechst 33258 dye
(Life Technologies) and consecutive readout on a multimode
microplate reader (TECANM200 PRO) (67).
Osteogenic Induction
BMSCs were cultured with complete DMEM-LG supplemented
with 0.1µM dexamethasone, 50µM ascorbic acid, and 10mM
beta-glycerol-phosphate disodium salt hydrate (all Sigma-
Aldrich). Osteogenesis was assessed by Alizarin Red S (Merck)
staining to determine mineralized matrix deposition, which was
quantified at days 14, 18, and 22 by measuring the absorbance
of Alizarin Red S and then normalized to the cell number
determined by Hoechst staining, with consecutive readout of
absorbance on the TECAN reader. The ALP activity level was
quantified by measuring the consumption of p-nitrophenyl
phosphate (pNPP; Sigma-Aldrich), which was normalized to
the amount of viable cell metabolic activity as measured by
PrestoBlue R© assay (Life Technologies) (67, 78).
Chondrogenesis
BMSCs (only at passage 6) were placed in V-bottom 96-
well plates, centrifuged and subsequently cultured for up to
21 days in a chondrogenic medium [FBS-free DMEM-HG
supplemented with 6.25µg/mL insulin-transferrin-selenium,
0.1µM dexamethasone, 50µg/mL L-Ascorbic acid 2-phosphate
sesquimagnesium salt hydrate, 1mM sodium pyruvate,
0.35mM L-proline, 1.25 mg/mL bovine serum albumin, 5.35
mg/mL linoleic acid (all from Sigma-Aldrich), and 10 ng/mL
transforming growth factor-beta-3 (TGF-beta; Peprotech)] (78),
and to quantify chondrogenesis, proteoglycan production was
normalized to total protein amount (67).
Immunomodulation, Endothelial Tube
Formation, and Cytokine Measurements
The immunomodulatory effects of BMSCs were assayed as
described previously (80). Human peripheral bloodmononuclear
cells (PBMCs) were stained with 5µM carboxy-fluorescein-
succinimidyl ester (CFSE; Life Technologies), stimulated with
anti-CD3 and anti-CD28 0.25µg/mL (Biolegend) or with
phytohemagglutinin (PHA; 0.5µg/mL; Sigma Aldrich), and co-
cultured with or without BMSCs at a ratio of 10:1. After 5 days,
the CFSE-labeled PBMCs were harvested, stained with antibodies
specific for CD4 and CD8 (anti-CD4-APC; anti-CD8-PE; both
Miltenyi), and subjected to analysis with flow cytometry.
For tube formation assay (81), human umbilical vein
endothelial cells (HUVECs) were plated in 96-well plates
coated with Matrigel (Corning) and co-cultured for 16 h with
conditioned culture medium derived from BMSCs or with
unconditioned blank control. Bright-field microscopic images
of each well were taken for computer-assisted quantification
of multiple parameters associated with endothelial network
formation, e.g., total master segment length (TMSL/field)
(ImageJ 1.51; Bethesda, USA). For the generation of BMSC-
conditioned media, the cells were seeded at a density of 1 ×
104 cells/cm2 in 24-well plates (DMEM + 10%FCS), allowed to
adhere overnight, washed once to remove residual protein, and
cultured for 24 h with media containing 0.5% FCS to collect the
cells secretome. The conditioned a medium was collected and
centrifuged to remove cell debris and supernatants, filtered, and
stored at −80◦C until assayed. Levels of interleukin 6 (IL-6) and
vascular endothelial growth factor (VEGF) were assayed by using
enzyme-linked immunosorbent assays (ELISA; R&D Systems).
Exploratory and Descriptive Statistics
Statistical analyses were performed using ANOVA and the
Student’s t-test. All data sets from individual experiments were
tested for normal distribution with the Shapiro-Wilks test prior
to testing for statistical significance. When performing multiple
pair-wise comparisons, one way or two-way ANOVA was used,
and Bonferroni post-hoc corrections were performed to adjust
the p-values. For single-group testing, statistical significance was
tested by Student’s t-test (paired or unpaired, two-tailed). If the
data did not fit a normal distribution, the Mann-Whitney test or
theWilcoxon matched-pairs test was used (two-tailed confidence
intervals, 95%; P < 0.05 was considered statistically significant;
Prism 5.0; Graphpad Software, USA).
RESULTS
Donor Stratification, Phenotypic, and
Growth Characteristics of BMSCs
This study included BMSC preparations from 10 adult (38.2 ±
11.1 years) and 13 elderly (72.2± 7.5 years) donors, selected upon
stratification of clinical background, to dissect the influence of
donor age and common comorbidities (Table 2). We found that
60% of the adult cohort and 100% of the elderly cohort presented
with comorbidities, with diabetes mellitus in 10% (1/10) and
54% (7/13) of cases (mainly early-stage, 6 non-insulin, and 2
insulin-dependent), respectively, followed by hypertension and
other cardiovascular complications.
For both the adult and elderly cohort, the BM used as
the starting material for cell isolation had a similar sample
weight (Figure 1A, left panel), content of BM-MNCs (Figure 1B,
left panel), and BMSC frequencies (Figure 1C, left panel).
Stratification according to non-diabetic and diabetic donors also
resulted in a comparable sample weight (Figure 1A, right panel),
number of BM-MNCs (Figure 1B, right panel), and BMSC
content (Figure 1C, right panel). Independent of donor age or
diabetic status, the isolated BMSCs exhibited similar growth
kinetics, as quantified by cumulative population doublings at
passages 3 to 6 (Figure 1D). We observed a trend of reduced cell
growth with increasing passage number in some of the BMSC
preparations generated from the elderly diabetic donors with
multiple comorbidities (see below).
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P127 F 16 None None None
P264 F 25 None None None
P276 F 48 Yes (2) Yes (NID) Bone cyst
P285 F 35 None None None
P289 F 45 None None None
P293 M 48 Yes (1) None Hypertension
P308 F 47 Yes (1) None Hypertension
P357 M 37 Yes (1) None Hyperuraemia
P784 M 33 Yes (1) None Hypertension
P819* F 48 Yes (1) None Hypertension
Adults 3 / 7 38.2 ± 11.1 6 / 10 (60%) 1 / 10
(10%)
6 / 10 (60%)
P237 M 61 Yes (4) Yes (NID) Hypertension,
HPLA, and RA
P265 M 63 Yes (1) None Hypertension
P278 F 82 Yes (2) None Hypertension
and
Hyperuraemia
P316 F 71 Yes (2) Yes (NID) Hypertension
P336 M 80 Yes (3) Yes (NID) Haematuria and
Bradycardia
P354 M 85 Yes (2) Yes (NID) Hypertension
P374 M 68 Yes (1) None Hypertension
P378 M 78 Yes (1) None Hypertension
P386 F 68 Yes (1) None Hypertension
P651 F 69 Yes (1) None Hypertension
P660 F 65 Yes (2) Yes (NID) Hypertension
P777 F 73 Yes (4) Yes (ID) Hypertension,
CKD3, and HVI
P821* F 75 Yes (6) Yes (ID) Hypertension,
CKD3, and
HVI/DVT/PE




13 / 13 (100%)
The age range is defined as follows: Adults younger than 50 years, and Elderly older than
60 years, and age values are presented as mean ± SD. The main type of comorbidity
studied is diabetes mellitus. (*)Patients 819 and 821 were only included in Figures 5,
6. CKD3, chronic kidney disease grade 3; HLPA, hyperlipoproteinemia; HVI, heart valve
insufficiency; DVT, deep-vein thrombosis; PE, pulmonary embolism; RA, rheumatoid
polyarthritis; and NID/ID, non-insulin-/insulin-dependent diabetes mellitus.
Phenotypic profiling revealed that all of the isolated BMSC
cultures had a typical fibroblast-like morphology that was
preserved during in vitro expansion up to passage 6 (Figure 2A
and Figure S1). Regardless of donor age, trypsin-detached
spheroid BMSCs had similar cell diameter and volume values
at passage 3 (Figure 2B and Figure S1). Cells from adult and
elderly donors, however, exhibited an increase in cell diameter
and volume with increasing culture time, though this difference
only reaches static significance between BMSCs derived from
elderly donors at passages 3 and 6 (P < 0.001). BMSCs from
FIGURE 1 | Primary isolation and growth kinetics of BMSCs. (A–C) Quality
control of BM samples: (A) bone marrow sample weight (in grams) and (B)
number of BM-MNCs per sample (cells/cm3 ), (C) number of BMSCs per
sample (cells/cm3 ), and (D) growth kinetics of BMSCs, with population
doublings determined at different passages (P3-6), were quantified for BMSC
preparations from adult vs. elderly (n = 9 vs. 12) and for non-diabetic vs.
predominantly non-insulin-dependent early-stage diabetic donors (n = 14 vs.
n = 7). Data are shown as mean ± SD, and the statistics were evaluated with
a Student’s t-test.
diabetic donors showed a similar trend of increased cell size and
volume, especially at higher passages, but this was not significant
(Figure 2B).
Analysis of the cell surface marker pattern revealed that all
of the BMSC preparations exhibited a similar surface marker
phenotype at passage 3, as defined by the ISCT criteria (69),
independent of donor age and disease status (Figure 2C).
The isolated cells express typical MSC markers (CD73, CD90,
CD105, and CD146) while being negative for contaminating
cell populations (CD14, CD19, CD31, CD34, and CD45) such
as cells of myeloid, B-cell, endothelial, and hematopoietic
origin, respectively.
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FIGURE 2 | Morphology and immunophenotype of BMSCs. (A) Representative bright-field microscopy images of BMSC cultures at passage 3 and 6, comparing
adult vs. elderly and non-diabetic vs. diabetic donors, showing typical fibroblast-like morphology with a trend toward more irregular morphology in diabetic donors; (B)
analysis of cell size and cell volume of trypsin-detached BMSCs from adult vs. elderly (n = 9 vs. 12) and non-diabetic vs. diabetic donors (n = 14 vs. 7). Adult and
elderly have similar cell size and volume at passage 3, and the cell size of adult donor-derived BMSCs does not increase with passages, while elderly donor-derived
BMSCs display cell enlargement with increasing passage; and (C) flow cytometry analysis of BMSCs (% positive cells; n = 6 random adult or elderly donors at early
passage 1–3) with representative histograms shown to the right (unlabeled controls are shown in solid gray). The cells highly express typical BMSC-associated
markers CD44, CD73, CD90, and CD105 while exhibiting no/weak expression of non-MSC-associated markers CD14, CD31, CD34, and CD45. Data are shown as
mean ± SD, and statistical evaluation was performed by Student’s t-test (*P < 0.05 and ***P < 0.001).
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Interestingly, we noted a weak decline in the expression
of CD105 (P < 0.05 to P < 0.001) and CD146 (P < 0.01
to P < 0.001) upon extended culture up to P6 in all BMSC
preparations, suggesting that long-term culture had a negative
impact on the MSC phenotype of the cells. Indeed, a weak
decline in CD105 and a stronger decline in CD106- and CD146-
expression after extended culture, particularly in DMEM-media,
or upon repeated passaging, have been reported previously (82).
Functionally, the altered expression of CD105 was found to be
associated with decreased osteogenic potential and altered Notch
signaling (83).
In vitro Aging, but Not Donor Aging Alters
the Transcriptome of Biobanked BMSCs
Next, we studied whether subgroups of BMSCs under
resting conditions differed in their gene expression profiles
by performing global transcriptome analysis. Multivariate
statistical analysis using principal component analysis (PCA)
was performed to study the variability between the groups
with subsequent visualization of significant differences by
hierarchical clustering heat maps and gene-ontology (GO) term
enrichment analysis.
Our PCA-analysis found no clear separation between
unstimulated BMSCs at P3 either for the comparison of adult
and elderly (n = 9 vs. n = 12 donors) or non-diabetic and
diabetic (n = 14 vs. n = 7 donors) donors (Figure 3A, left and
central panel). Our diabetic group consisted of one adult and six
elderly donors, and thus the comparison between non-diabetics
(8 adults and 6 elderly) and diabetics is mainly a comparison
with elderly diabetics (86% of the group), which could potentially
weaken this analysis. To clarify this point, we carried out a sub-
stratified comparison only between elderly diabetic and elderly
non-diabetic donors (n = 6 each) (Figure S2). However, this
analysis came to the same conclusion as the prior comparison
and revealed no apparent differences in transcriptome between
the two groups.
This result could suggest either, that the RNA sequencing-
obtained gene-expression profiles of our isolated and in vitro
expanded BMSCs are not affected consistently enough by
the parameters age or diabetic status to allow for a robust
multivariate statistical separation of these groups under resting
conditions or, alternatively, that the studied in vivo imprint of the
donor (e.g., aging and mild comorbidities) is simply not strong
enough or is not maintained after isolation and in vitro expansion
for several weeks.
Thus, as a positive control, we compared the gene expression
pattern of selected donors from the same cohorts at P3
and P6 (n = 6 per group). We detected a clear difference
between the two groups (Figure 3A, right panel) that confirms
earlier reports (16, 38, 54). Our PCA showed a 32% variance
in PC1 and 24% variance in PC2, indicating that PC1
(influence of culture time) accounts for most of the observed
differences in expression pattern between the two groups.
Accordingly, a subsequent hierarchical clustering analysis
separated the transcriptome of BMSC preparations by their
number of passages into two distinct P3 and P6 groups
(Figure 3B).
The “Top 10 Results” from GO-term enrichment analysis
of the biological processes predominantly involved identified
highly significant changes in gene signatures associated with
cell cycle, nuclear cell division, and chromosome segregation
(Figure 3C). Concomitant in-depth delineation of the biological
process and molecular functions involved using a combined
DAVID and GO-database “Top 8 Results” analysis (Figure 3D)
revealed that the altered biological processes were associated
with changes in cytoskeletal proteins and microtubule binding,
tubulin, fibronectin, enzyme, and protein kinase binding and
kinase activity.
In summary, we found that the process of BMSC in vitro
expansion had a strong impact on molecular phenotype, which
may mask any rather weak in vivo imprint from donor aging
and associated mild comorbidities after expansion over several
passages in culture, as is typically done for cell production and
biobanking. This does not generally exclude potential differences
becoming apparent for the assessment of larger age differences
(e.g., when comparing very young vs. elderly donors) or when
studying the impact of stronger comorbidities.
In order to understand the functional heterogeneity of BMSC
preparations, we next analyzed their functional performance
in multiple in vitro assays typically employed for BMSC
characterization (84).
In vitro Aging, but Not Donor Aging Affects
BMSC Differentiation Capacity
In accordance with the prior transcriptome analysis setup, we
studied the differentiation capacity of BMSCs depending on
donor age and diabetic status with adjunct comparison of
passages 3 and 6 (Figure 4 and Figures S3, S4). In line with
the prior results, we did not find any major differences in the
differentiation capacity of BMSC preparations with respect to
donor age and the presence of early-stage mild diabetes in the
donor cohort under standard culture conditions (Figures 4A–C
and Figure S4).
Along with the transcriptome changes observed during
replicative in vitro aging, we compared the differentiation
capacity of BMSC toward osteogenic and adipogenic lineages
between P3 and P6 in order to evaluate whether the substantial
transcriptional changes may also reflect alterations in functional
behavior (Figures 4A,B). Indeed, BMSCs from adult and
elderly donors exhibited significantly diminished osteogenic
differentiation at passage 6 compared with passage 3 (P <
0.01 and P < 0.001, Figure 4A), which was also evident for
comparison of non-diabetic and diabetic donors at both
passages (P < 0.001 and P < 0.05). In contrast, adipogenic
differentiation potential only showed minor changes, mainly
reduced lipid formation, when comparing early and late
passages or at later readout (P < 0.05, Figure 4B). The
BMSCs from both adult and elderly donors displayed a similar
increase in proteoglycan production upon chondrogenic
differentiation with an induction medium containing
transforming growth factor-beta (TGF-β) (P < 0.01 and P
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FIGURE 3 | Gene-expression-profiling of BMSCs with RNA-sequencing. (A) Principle component analysis (PCA) was employed for the visualization of group
separation. Groups were stratified either according to donor age (left panel; n = 9 adult vs. n = 12 elderly donors), health status (central panel: n = 14 non-diabetic vs.
n = 7 diabetic donors), and passage number (right panel; n = 6 random donors at passage 3 vs. 6). The PCA showed clear separation when comparing passage 3
vs. 6 (right panel), but no separation for the comparison of adult vs. elderly or diabetic vs. non-diabetic donors, with a random dot distribution throughout the graph.
(B–D) passage 3 vs. 6 comparisons: (B) hierarchical clustering heat map with expression values sorted according to donor (rows) and gene (columns), where low
expression is denoted by blue and high expression by red; (C) gene ontology (GO) enrichment analysis, with the “Top 10 Results” for changes in biological process
(e.g., cell cycle, nuclear and cell division, and chromosome segregation) shown on the left y-axis and the size of the dots representing the counts of genes involved,
while the color of the circle (scaled blue/lowest to red/highest) indicates significance expressed as adjusted p-value. (D) Combined David and GO “Top 8 Results”
database analysis for changes in biological process (left panel; e.g., mitotic cell cycle and nuclear division) and molecular function (right panel; e.g., cytoskeletal protein
binding and microtubule binding), with the z-score indicating the overall decrease or increase in expression for certain GO terms and the log-FC analysis indicating the
actual number of down- or up-regulated genes within a certain GO term.
< 0.001, Figure 4C). BMSCs from non-diabetic and early-stage
diabetic donors displayed similar chondrogenic differentiation
capacity upon induction with the specific differentiation
medium, thus excluding any major detectable influence of
advanced BMSC donor age or diabetic status on chondrogenic
differentiation capacity.
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FIGURE 4 | Multilineage differentiation potential of BMSCs. The differentiation capacity of MSCs from adult and elderly (n = 9 vs. 12) and non-diabetic and
predominantly non-insulin-dependent early-stage diabetic donors (n = 14 vs. 7) was assessed with different in vitro assays. (A) Osteogenic differentiation was
assessed by quantification of BMSC matrix mineralization upon osteogenic induction for 14, 18, and 22 days, with representative images for Alizarin red staining
shown at the top. Quantification revealed a time-dependent increase in mineralization for all groups (day 14 vs. day 22) both at passages 3 and 6, while there was no
difference between adult vs. elderly or non-diabetic vs. diabetic donors at either time point or passage but a strong reduction in mineralization for higher vs. lower
passage cells (P6 vs. P3). (B) Adipogenic differentiation of BMSCs upon in vitro adipogenic induction for 10 and 14 days was quantified by staining of lipid-rich
vacuoles with Nile Red, with representative images for vacuole formation shown at the top. Quantification revealed similar vacuole formation for both time points (day
10 vs. day 14), with a trend of modest reduction when comparing higher vs. lower passage cells (P6 vs. P3). There was again no difference between adult vs. elderly
or non-diabetic vs. diabetic donors at either time point but a stronger passage-dependent reduction for cells from elderly or diabetic donor donors (P3 vs. P6), though
this was less notable for cells from adult or non-diabetic donors. (C) Chondrogenic differentiation of BMSCs upon induction with TGF-beta was quantified as the ratio
of proteoglycan synthesis relative to protein content, with representative histology images for alcian blue proteoglycan staining of pellet sections shown to the right.
There was no difference between BMSCs from adult vs. elderly or non-diabetic vs. diabetic donors. Data are shown as mean ± SD, and statistical evaluation was
performed by using a Student’s t-test or ANOVA followed by post-tests (*P < 0.05, **P < 0.01, and ***P < 0.001).
Frontiers in Immunology | www.frontiersin.org 13 November 2019 | Volume 10 | Article 2474
Andrzejewska et al. BMSC in vivo and in vitro Aging
We found that assay readout-time had a considerable
confounding influence on the obtained results, e.g., when
comparing mineralization at day 14 to day 22 for cells at passage
3 and 6 (P < 0.05 to P < 0.001, Figure 4A) or when studying the
optimal time point for the assessment of ALP-activity, which was
found to be highest on day 5 for both adult and elderly and both
non-diabetic and diabetic cohorts at passage 3 and 6 (Figure S3).
This assay-readout time-dependence was less evident for the
assessment of adipogenic differentiation (Figure 4B), e.g., when
comparing day 10 and 14 at passages 3 and 6. Interestingly, we
could detect weakly compromised lipid formation for BMSCs
from elderly donors (P < 0.05, Figure 4B).
Cytokine Challenge in vitro Reveals Altered
Gene Regulation in BMSCs From Select
Elderly Donors With Multiple Comorbidities
Many clinical applications of BMSCs involve the therapeutic
delivery of the cells into challenging in vivo environments
characterized by inflammation or anoxia (13). Thus, it is indeed
advisable to conduct cell-profiling approaches under resting
and stimulating conditions (Figure 5A) (85). Stimulation with a
cytokine cocktail resulted in a clear separation into two distinct
groups in the hierarchical clustering heat map (Figure 5A), with
multiple changes in biological processes such as immune system
process or immune and inflammatory responses, as typically
observed upon cytokine challenge of MSCs, e.g., during potency
analysis of MSC products (85, 86).
Substratified expression analysis focusing only on stimulated
samples found (Figure 5B), that BMSCs from the two elderly
donors with insulin-dependent diabetes and multiple other
comorbidities (P777 and P821, n = 4 and n = 6 comorbidities,
respectively) clustered differently from the elderly and adult
donors with fewer comorbidities (P265 and P374; and P264,
P784, and P819, n = 0–1 comorbidities each). However, this has
to be interpreted with caution since the number of donors with
multiple comorbidities in this analysis was very limited due to
their rare occurrence in our biobank. Indeed, changes in BMSC
transcriptome upon disease progression to amore advanced stage
(e.g., in advanced insulin-dependent diabetes and renal failure)
have been reported earlier (55, 58, 60).
In our study, this was associated with a decline in cell
proliferation and progression from a regular to a more
irregular cell morphology in culture, particularly for BMSCs
from elderly donors with insulin-dependent diabetes and
multiple comorbidities (Figure 5B, lower panel). Analysis
of the biological processes that differ in BMSC specimens
from the two elderly donors with multiple comorbidities
(Figure 5B, right panel) identified the downregulation of
processes associated with cell proliferation (e.g., mitotic cell
cycle, cell division, chromosome organization, and organelle
fission). In contrast, upregulated processes entailed categories
associated with cell differentiation (e.g., multicellular organism
process, anatomic structure development and morphogenesis,
and ECM organization), thus potentially indicating a progressive
loss of the MSC “stem cell” phenotype over time in the
presence of multiple strong comorbidities, although any
conclusions from this analysis are limited due to the small
sample size.
Inflammatory Challenge Affects BMSC
Paracrine Activity
The prior assays involving advanced donor age and the
predominant early-stage diabetic status of the included
patients showed only minor effects on the in vitro expansion
and differentiation capacity, as well as the transcriptome
of unstimulated BMSCs. The subsequent experiment of in
vitro cytokine challenge demonstrated a degree of altered
responsiveness on the transcriptome level in BMSCs with
advanced donor comorbidities.
In line with these transcriptome changes, we observed more
pronounced effects on the secretome and paracrine activity of
cytokine-activated BMSCs upon environmental challenge by an
inflammatory environment (Figure 6), e.g., upon stimulation
with pro-inflammatory cytokines and consecutive readout of
angiogenesis in response to their secretome (conditioned media).
We found that their immunomodulatory activity to suppress
T-cell proliferation was not altered, thus confirming that this
is a rather well-preserved process, even if cells are obtained
from donors with advanced diabetes and renal failure (55).
Nonetheless, the overall impact of these donor parameters on
BMSC function was rather modest.
BMSC preparations from both adult and elderly donors and
both non-diabetic and diabetic donors effectively suppressed
CD8 and CD4 T-cell proliferation in either anti-CD3/CD28
or PHA-stimulated PBMC cultures (Figure 6A). The average
remaining proliferation of CD8-responses for adult and elderly
BMSCs was 15.9 ± 7.2% and 10.3 ± 6.0% for anti-CD3/CD28-
stimulated cultures (P< 0.05 and P< 0.001) and 17.7± 9.0% and
12.1± 8.7% for PHA-stimulated cultures compared to control (P
< 0.05 and P < 0.001), with no significant differences between
adult and elderly groups for the two different stimuli (P = 0.06
and P = 0.16, respectively).
The average suppression of CD4-responses was generally
weaker, with a remaining proliferation of 46.7 ± 28.7% and
27.9 ± 20.8% for anti-CD3/CD28-stimulated cultures (P < 0.05
and P < 0.001) and 38.0 ± 23.3% and 27.6 ± 19.8% for PHA-
stimulated cultures compared to control (P < 0.05 and P <
0.001), with no significant differences between adult and elderly
groups for the two stimuli (P= 0.09 and P= 0.3, respectively). A
similar suppression pattern of CD8 and CD4 T-cell proliferation
in anti-CD3/CD28- or PHA-stimulated co-cultures was found
for BMSCs from non-diabetic and diabetic donors (All P < 0.01
and P < 0.05), while again no significant differences were found
between non-diabetic vs. diabetic donors.
Next, we analyzed the secretion of IL-6 and VEGF, two key
paracrine mediators associated with BMSC function (Figure 6B).
Both, adult and elderly donor-derived BMSCs demonstrated
strong secretion of IL-6 compared to the negative control
medium (P < 0.01 and P < 0.001, mean 806 vs. 1,300 pg/mL),
with higher IL-6 secretion in BMSC-conditioned media from
elderly compared to adult BMSC donors (P < 0.05). Similarly,
we detected a strong secretion of VEGF by both types of BMSCs
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FIGURE 5 | Cytokine challenge reveals altered gene regulation in BMSCs from elderly donors with multiple comorbidities. (A) Comparison of unstimulated vs.
cytokine-stimulated BMSCs (n = 7 donors each): hierarchical clustering heat map with expression values sorted according to donors (rows) and genes (columns),
where low expression is denoted by blue and high expression by red, and corresponding gene ontology (GO) enrichment analysis with the “Top 10 Results” for
changes in biological process (e.g., immune system process and immune and defense response) shown on the left y-axis, and the size of the dots representing the
counts of genes involved, while the color of the circle (scaled blue/lowest to red/highest) indicating significance expressed as adjusted p-value. (B) Substratified gene
expression analysis focusing only on stimulated samples (n = 7 donors): BMSCs from elderly donors with multiple comorbidities (P777 and P821, with n = 4 and n =
6 comorbidities, respectively) cluster separately from both elderly and adult donors with few comorbidities (P265 and P374; and P264, P784, and P819, respectively,
n = 0–1 comorbidities), indicating that the accumulation of multiple comorbidities during advanced age results in a detectable in vivo imprint in the transcriptome of
BMSCs. This was accompanied by a decline in cell proliferation and a progression from regular to irregular morphology in culture (representative images at the
bottom), resulting in a progressive loss of contact inhibition and cell aggregation. Analysis of the biological processes, showing that P777 and P821 differ under
stimulating conditions from the other donors, identified significant downregulation of processes associated with cell proliferation (e.g., mitotic cell cycle, cell division,
and chromosome organization), while upregulated processes entailed categories associated with cell differentiation (e.g., multicellular organism process, anatomic
structure development, morphogenesis, and ECM organization).
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FIGURE 6 | Immunomodulatory and paracrine activity of BMSCs. (A) Immunomodulatory activity of BMSCs (n = 9 adult vs. n = 12 elderly and n = 14 non-diabetic
vs. n = 7 diabetic donors, passage 3) to suppress anti-CD3/CD28- or phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cell (PBMC)-proliferation.
The PBMCs were labeled with the cell proliferation-tracker dye CFSE, activated with either of the two different stimuli, and cocultured for 5 days with BMSCs from
adult or elderly donors, in order to assess their capacity to inhibit the proliferation of CD4+ and CD8+ T-cells with flow cytometry, with representative histograms
shown to the right. The quantitative assessment of T-cell proliferation is expressed as the percentage proliferation of CD4+ and CD8+ T cells relative to the positive
control without BMSCs. Both adult vs. elderly and non-diabetic vs. diabetic donor-derived MSCs are equally potent in inhibiting CD4 and CD8 T-cell proliferation.
(B,C) Paracrine and proangiogenic activity of BMSCs (n = 9 adult vs. n = 12 elderly and n = 14 non-diabetic vs. n = 7 diabetic donors) with and without cytokine
stimulation (10 ng/mL of TNF-alpha and IFN-gamma for 24 h): (B) secretion of IL-6 and VEGF (pg/mL) in BMSC-conditioned culture media was assessed with ELISA,
detecting elevated levels of IL-6 secretion by BMSCs obtained from elderly or diabetic donors, and (C) proangiogenic activity of BMSC-conditioned media compared
to blank group (medium only) in an endothelial tube formation assay, with a representative image for the quantification of endothelial network formation by
quantification of the total master segment length (TMSL/field, with 3–5 images assessed per test condition); TMSL/field was slightly increased for adult and
non-diabetic donors. Results are given as box plot ± min-max whiskers. Statistical analysis was performed using either a Student’s t-test or ANOVA followed by
post-tests (*P < 0.05, **P < 0.01, and ***P < 0.001).
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compared to negative controls (Both P < 0.001, mean 3,033
vs. 2,840 pg/mL), although there was no significant difference
between the age groups.
Interestingly, IL-6 and VEGF were inversely regulated
upon pro-inflammatory challenge with tumor necrosis factor-
alpha (TNF-a) and interferon-gamma (IFN-g), with significant
upregulation of IL-6 (P < 0.05) but downregulation of VEGF
(P < 0.05) in stimulated cells compared to resting controls,
thus demonstrating an inverse relationship between the two
factors under stimulating conditions. Importantly, both BMSCs
from adult vs. elderly donors and from non-diabetic vs. diabetic
donors showed differential secretion of VEGF upon cytokine
stimulation (P < 0.01 and P < 0.05), which was not the case
for IL-6.
When exposing endothelial cells (ECs) to BMSC-conditioned
culture medium from adult vs. elderly or non-diabetic vs.
diabetic donors (Figure 6C), we found increased proangiogenic
activity with media from adult donors compared to negative
control (P < 0.05, mean 2,551 vs. 4,131 TMSL/field), while
conditioned media from elderly donors and the comparison
of adult and elderly donors did not reveal any differences.
BMSC conditioned medium from non-diabetic donors showed
the most profound proangiogenic activity compared to
control (P < 0.05).
These results taken together indicate a weak but
notable influence of advanced donor age and early-stage
diabetes on BMSC regulation of its paracrine activity in
response to cytokine challenge, while this was less evident
for its immunomodulatory activity to suppress T-cell
proliferation in vitro.
DISCUSSION
The goal of this study was to understand heterogeneity
among BMSC specimens, which are frequently considered
for autologous therapy approaches. We asked whether
the donor-specific variability in morphological and
functional parameters could be explained by intrinsic
cell-donor attributes such as variations in donor age
and common comorbidities. We thus conducted donor
stratification and multi-parameter analysis in a defined
patient cohort to allow for a robust readout of individual
assay parameters.
Previous studies investigating the impact of donor age
and comorbidities on BMSC properties reported partially
inconclusive or contradictory outcomes (Table 1). We
hypothesized that BMSCs from elderly donors (>60 years),
who commonly suffer from mild comorbidities, display
reduced regenerative function compared to adult donors (<50
years), who were found to have a much lower burden of
common comorbidities. To our surprise, we found that for
our prospective stratification, both adult and elderly donors
demonstrated on average rather similar performance in most
assays and that in vitro aging rather than in vivo aging and the
typically associated mild comorbidities predominantly affected
BMSC properties.
Clinical and Biological Relevance of Donor
Aging for BMSC Biobanking Approaches
Many of the treatment indications targeted by allogeneic and
autologous BMSC therapies are associated with advanced age,
thus making elderly patients with multiple comorbidities one
of the high-demand groups for cell-based therapies. They are
thus frequently found among the cell donors of our biobank
(1). The donor age of BMSC donors is one of the most clearly
defined and readily accessible parameters and has been widely
investigated, while the impact of certain comorbidities associated
with advanced age is more difficult to assess.
Both, autologous and allogeneic BMSC therapies are widely
studied, and it is not clear yet which approach will be favored
for specific treatment indications (87). Allogeneic approaches
provide the great advantage of being able to choose a well-defined
starting material, e.g., from developmentally young tissue such as
placenta or umbilical cord blood. However, they may come at the
cost of immunological incompatibility, which may compromise
efficacy and lead to allo-sensitization of the patient. Thus, a major
advantage of autologous approaches is their neutral immune
profile, but they may be limited by compromised bioactivity of
cells sourced from elderly donors with multiple comorbidities,
complex diseases, and pharmacological regimens (18, 19, 88).
Many studies focusing on BMSCs in the context of
aging have compared various parameters either in cells from
younger vs. elderly donors or the impact on cell expansion.
These were mainly: (1) Cellular phenotype and proliferation
capacity, (2) Gene expression profile, and (3) Various functional
parameters, such as mesodermal differentiation capacity and
immunosuppressive and paracrine properties. A problem with
BMSC characterization is the great number of potentially
confounding experimental variables that may impede the readout
(85, 89).
BM-Sample Cellularity, BMSC Growth,
Morphology, and Immunophenotype
Multiple studies have reported a decline of BM cellularity (e.g.,
BM-MNC and BMSC), CFU-F capacity, and growth kinetics
with advanced donor age (17, 27, 29–31, 34). BMSCs have been
shown to demonstrate a logarithmic decline with increasing age
(31, 90), most evidently in the first years of life (e.g., newborns
1/10.000 and teens 1/100.000 BMSCs per BM-MNC), but this was
less evident in later life, e.g., when comparing adults vs. elderly
donors (e.g., 35-year old 1/250.000, 50-year old 1/400.000, and
60-year old 1/2-million BMSCs per BM-MNC). In our study, we
could not detect an age-related difference in cellularity, showing
that BM aspirates from adult donors had similar cell content
as those from elderly donors (mean 38 vs. 72 years). We could
thereby minimize a major confounding sampling bias in the
starting material that may have caused initial disparities between
the stratified groups.
In prior studies, differences in cell growth were most evident
when comparing pediatric vs. elderly donors (27, 34), e.g., defined
as the age ranges of 1–5 years vs. 50–70 years, respectively (34). In
our study, we found no significant differences in the proliferation
of BMSCs from adult and elderly donors, whichmay be explained
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by the different time-windows of analysis (Mean 38 vs. 72 years),
since the donor population from our biobank does not include
pediatric patients and contains few young adults. Our findings
are in line with a report by Siegel et al. (33), who also found no
correlation between the growth rate of BMSCs and donor age.
Nonetheless, we could observe a trend of declining proliferation
with successive passages, in particular in BMSCs from elderly
donors with multiple comorbidities, although, surprisingly, this
was not significant for the entire cohort.
Several reviews have summarized the impact of patient-
specific aging and comorbidities on the morphological
parameters of BMSCs (18, 19, 91), highlighting cell enlargement,
decreased proliferation and replicative quiescence- and
senescence-associated ß-galactosidase, as also discussed earlier
(26). Siegel et al. reported an impact of donor aging on cell size
(BMSCs at P1 from younger donors were smaller) and surface
marker expression profile (e.g., increased levels of integrins,
PDGFR-beta, and CD90 in younger donors).
In contrast to Siegel et al., who assessed the cell size at passage
one, we assessed both cell size and volume of BMSCs at passage
three and found that chronological aging had a rather minor
influence, which may be due to the longer culture period (two
passages longer). Nonetheless, we observed that BMSCs from
elderly individuals, but not the younger donors, were more prone
to an increase in cell size and volume at later passage (P6). This
may support the notion of the so-called “Hayflick limit,” the
earlier reaching of proliferative senescence in cells from aged
donors that is commonly observed in primary cells (16, 49).
Furthermore, a recent review by Baker et al. suggested that
extended in vitro cultivation might alter the immunophenotype
of BMSCs (17). We analyzed the cellular surface markers
proposed by ISCT (69), and found that BMSCs from adult
and elderly donors at both passages express typical MSC-
associated markers, CD73, CD90, CD105, and CD146 and
were negative for CD14, CD31, CD34, and CD45, with a
limited influence of passage (decrease of CD105 and CD146).
However, we observed that the expression of CD105 and CD146
declines with increasing passage number, suggesting a potential
relationship between altered cell surface marker pattern and
reduced functional capacity.
Indeed, reduced expression of CD105, CD106, and CD146
after extended culture and repeated passaging, particularly when
the cells are cultured in DMEM-media, has been reported
previously (82). Surface expression of CD105 can also be affected
by the mode of culture (e.g., flasks vs. bioreactor or enzymatic
detachment) (92). Downregulation of the TGF-beta receptor
endoglin (CD105) and its associated signaling pathways (e.g.,
the Notch pathway) may also partly explain the evident decline
in osteogenic differentiation capacity in BMSCs at increasing
passage number (83).
BMSC Gene Expression Studies
So far, only a small number of studies have comprehensively
studied the influence of advanced donor age and comorbidities
on the transcriptome and methylome of BMSC products, mainly
focusing on the effects of in vitro expansion before entering the
senescent state (38, 93).
Our PCA of RNA-sequencing-derived gene expression
profiles of unstimulated resting BMSC samples at early passage
(P3) showed no clear separation between adult vs. elderly or non-
diabetic vs. early-stage diabetic donors (both analysis of the whole
cohort n = 14 vs. 7 or for the sub-stratified analysis of elderly
non-diabetics vs. elderly diabetics n = 6 each). We compared
non-diabetic vs. diabetic donors, since this was themost common
and well-defined comorbidity in our cohort and is also frequently
studied by others (60).
It should be noted that the majority of our diabetic
donors suffered from non-insulin-dependent early-stage type 2
diabetes and that only two of the donors had more advanced
insulin-dependent type 2 diabetes and multiple other notable
comorbidities, owing to their rare presence in our biobank.
However, the two donors with a more advanced disease stage
in particular demonstrated differential gene expression upon
cytokine challenge, corresponding to gene pathways associated
with cellular decline. Davies et al. reported previously that
BMSCs from late-stage type 1 diabetic donors show significant
alterations in transcriptome compared to healthy controls under
resting conditions (55). Indeed, patients who are affected by
advanced late-stage type 1 or type 2 diabetes often present with
renal failure and other more serious comorbidities and were thus
on average sicker than the donors included in our analysis, which
may explain the difference (60).
Furthermore, a recent methylome analysis of young and aged
adults (n = 5 each, mean 22 vs. 75 years, range 20–24 vs.
62–82 years, respectively) at early and late passage (P4 vs. P8)
was prospectively designed to distinguish between donor-age-
and culture-induced changes (93). The authors found that a
larger number of CpGs were differentially methylated in aged
donors during culture and biological aging while there were fewer
changes in young donors across genic elements, indicating that
younger donors are more refractory to culture-induced changes.
Furthermore, it was found that the majority of methylation
changes appeared to be specific to either young or aged donors,
with a subset being specific to long-term culture irrespective of
adult donor age.
We also found in our second set of experiments under
cytokine-challenge that particular elderly donors with multiple
comorbidities (e.g., insulin-dependent diabetes and renal failure)
demonstrated differential gene-expression profiles to healthy
adults and healthy elderly donors, although these results have
to be interpreted with great caution due to the small number
of available samples that could be included in this analysis.
Analysis of the underlying gene expression pathways indicated
that this was associated with a loss of stemness and increased
differentiation, going hand in hand with the observedmethylome
changes in the study above. This may indicate that, while
methylome changes between adult and elderly donors are
already evident in resting cells, transcriptome changes and their
functional impact may become more evident under challenging
environmental conditions.
As a positive control, we also analyzed how replicative aging
upon in vitro expansion influences the expression profiles of
BMSCs by comparing the gene expression pattern of six donors at
P3 and P6. We found a clear separation between the two groups,
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thus confirming earlier findings on thematter and demonstrating
the validity of our approach (16, 38, 54). Hierarchical clustering
heat maps showed distinct gene expression patterns, with a
passage-dependent decline in the expression of genes associated
with cell cycle and cell proliferation. Indeed, earlier studies
have demonstrated continuous and progressive gene-expression
changes in BMSCs upon long-term culture expansion (16, 38).
When comparing BMSCs at culture intervals from P2 up to
P11, gene expression changes accumulated with each additional
passage, with P2-3 vs. P4-5 vs. P6-11 being distinguishable,
demonstrating the great analytic power of the method.
Similarly, a recent study documented accumulating
transcriptome drift in UC-MSCs cultured until replicative
senescence, with transcriptome changes becoming evident at
P5, with a greater increase when reaching senescence at P9-12
(54), thus making it possible to distinguish between early passage
(P2-4), medium passage (P6-8), pre-senescent (P10-12), and
senescent (P14) cells. Both of these examples clearly illustrated
that in vitro expansion influences BMSC gene expression
signatures, which can dilute or mask any consistent in vivo
signatures associated with donor aging and comorbidities.
Functional Assessment: Differentiation,
Paracrine, and Immunomodulatory Activity
Since the key report by Pittenger et al. (84), themajority of studies
on BMSCs have assessed multilineage differentiation potential
as part of the minimal criteria for their characterization (69).
Importantly, those that have studied the impact of aging and
comorbidities often reported a negative impact of advanced
donor age, with differential effects on the individual lineages (e.g.,
osteogenic, chondrogenic, and adipogenic potential). A review
by Baker et al. pointed out that this is disputable and that
approximately half of the studies do not find differences (17).
Multiple reports have shown no effect or that osteogenic
differentiation decreases with increasing donor age (26, 29, 31,
33, 94). D’Ippolito et al. found a reduced ALP-positive CFU-F
number and osteogenic potential in younger vs. elderly donors
(3–36 vs. 41–70 years, respectively) (31). Müller et al. also
reported a strong donor-age related decline in the osteogenic
potential of BMSCs isolated from total hip arthroplasty patients
(≤50 years 7/11 or 63% positive, ≥60 years 5/19 or 26%
positive) (94).
Furthermore, Stolzing et al. reported that osteogenic and
chondrogenic potential were diminished with advanced age,
while adipogenic differentiation was not (29). However, others
found no age-dependent differences in differentiation capacity
for either lineage (24, 33, 45). This inconsistency between study
results may be explained by differences in methodology, e.g.,
using cells at different passages (26), as also indicated by our
transcriptome analysis.
We thus analyzed the differentiation potential of adult vs.
elderly and non-diabetic vs. early-stage diabetic donor-derived
BMSCs at both early and late passage (P3 vs. P6). We found that
the differentiation of BMSCs toward osteogenic, adipogenic, and
chondrogenic lineages was mainly independent of the age and
mild comorbidities of the donor and that in vitro aging, rather
than in vivo aging, had a notable impact.
A large share of the therapeutic activity of BMSCs is attributed
to their secretion of trophic and immunomodulatory factors
(95, 96), which can be modulated by the environment the cells
persist in or are brought into. Several reviews have summarized
how these properties are potentially altered in the context of
donor aging and its associated comorbidities (18, 21, 97).
Siegel et al. reported increased expression of IL-6 by BMSCs
in association with aging (33), while Efimenko et al. reported
reduced expression of VEGF and the loss of angiogenic potential
in elderly donors with cardiovascular complications who more
frequently presented with diabetes. We also found that BMSCs
from elderly donors produced higher levels of IL-6, while
both elderly and diabetic donors showed a stronger decline in
VEGF-production under stimulating conditions, which was also
reflected in lower in vitro angiogenic activity.
Considering their immunomodulatory activity, Siegel et al.
did not find a correlation between increased donor age and a
loss of immunomodulatory activity in BMSCs in a large cohort
of more than 50 donors aged 13–80 years (33). Furthermore,
two studies did not find a negative impact of diabetes when
comparing BMSCs from healthy donors either to early- and late-
stage type 1 diabetic donors (55) or to newly diagnosed type 1
diabetics (56). In contrast, Manchini et al. (n = 27 adult vs. n
= 23 elderly donors, cut-off 65 years) and Serena et al. (n = 4
donors each) reported a negative impact of age, atherosclerosis,
obesity and type 2 diabetes on the immunomodulatory properties
of adipose-derived MSCs.
Similarly to Siegel, Davies, and Yaochite and colleagues, we
did not observe any differences in the capacity of BMSC to
suppress CD4 or CD8 T-cell proliferation in anti-CD3/CD28- or
PHA-stimulated cultures with respect to age and comorbidities.
This may be explained by the rather weak comorbidities in our
patient cohort and the different age cut-offs for stratification of
the groups or by differences in methodology.
STUDY LIMITATIONS
Qualifying adult stem cell sources in biobanking approaches
is of major importance for understanding their behavior in
preclinical and clinical studies (1). Importantly, the results
obtained in most of the studies by other groups and also our
own studies are shaped by the starting material, cell isolation
and expansion protocols, and consecutive analysis methods. In
the following sections, we discuss a few prominent limitations
that are important for the interpretation of the results of this and
other studies.
Starting Material and Baseline
Characteristics of Diabetic Patients
Different outcomes considering an in vivo imprint of the cell
donor and tissue source may be obtained when using different
starting materials (e.g., adipose or placental tissue instead of
BM) (98). We have predominantly banked BM-MSCs at our
facility so far, and we can thus not extend our analysis to
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MSCs derived from other tissue sources in the same depth.
Our study is limited by the absence of control cells from
young and healthy volunteer donors from a commercially
available source, e.g., American Type Culture Collection (ATCC).
However, multiple MSC batches from young, healthy donors
isolated at our facility were included, and we here focused
on the clinically relevant patient population, who are most in
need of autologous BMSC-based therapies. Another important
aspect is the baseline characteristics of the patients and their
comorbidities, in particular the elderly diabetic patients. As
discussed above, the majority of the diabetic donors were non-
insulin-dependent early-stage diabetic (where few differences
were found), while two elderly donors with more progressed
insulin-dependent type 2 diabetes and multiple comorbidities
demonstrated more substantial phenotypic and functional
alterations in line with results from other groups (60), which
should be anticipated when interpreting the results for clinical
use of BMSCs.
Cell Isolation, Expansion, and Enzymatic
Detachment Protocols
Our protocol is based on one of the most commonly
used methods, separation of the BM-MNCs with density-
gradient centrifugation and plastic adherence, with culture
and expansion employing DMEM-LG containing 10% FCS. It
is noteworthy that alternative culture media (e.g., chemically
defined serum-/xeno-free MesenCult-XF medium or StemPro
XF and SF media) and growth supplementation (e.g., MSCGM
SingleQuots instead of 10% FCS) have become popular and
may yield different results when considering in vitro aging
and donor-specific in vivo imprint. Furthermore, our cell
detachment and passaging protocol is based on the most
commonly used protease trypsin, but other protocols (e.g.,
employing more gentle cell dissociation with dispase instead
of trypsin), may lead to different observations in terms
of in vitro aging, while it is rather unlikely that any in
vivo donor imprint is better preserved by using alternative
enzymatic detachment.
Transcriptome Analysis Method
Gene regulation at the post-transcriptional level is of great
importance in (adult) stem cells, and differences in transcriptome
or the lack thereof have to be interpreted with caution and
should not be equaled with proteome or functional conclusions.
We thus paralleled our transcriptome analysis with multiple
functional in vitro assays, partly under challenging inflammatory
conditions, to mimic the cells’ responsiveness in a disease
context (85, 86). We also used the known in vitro aging
effect during successive passaging as a positive control to align
transcriptional with functional outcomes. Novel methods such
as epigenetic methylome analysis and Ribo-profiling are of great
interest (93, 99). The latter attempts to better reflect the “active”
proteome by employing analysis of mRNA associated with
polysomes, which may more closely reflect the true levels of the
actively translated transcripts in the cells, although the method
is technically more challenging than the already established
RNAseq (99).
SUMMARY AND CONCLUSION
Our study demonstrates that donor age and its typically
associated mild comorbidities may exert less influence on the
phenotype and functionality of BMSCs than previously assumed
and that these two parameters do not explain the inherent
donor variation in our biobank. In fact, in vitro aging rather
than in vivo aging exerted a strong influence on the cellular
properties in our setting, with prolonged culture expansion
impairing the regenerative functions of BMSCs at later passages,
which should therefore be strongly controlled for in preclinical
and clinical studies. Therapeutic approaches would best require
a large number of minimally expanded cells with optimum
potency. Since sufficient BMSC numbers can only be obtained
by extensive expansion, this might be a limiting factor for
using BMSCs in cellular therapy, unless a sufficient amount of
starting material allowing for limited expansion can be obtained.
Alternative tissue sources with better expansion capacity (e.g.,
perinatal tissue sources such as placenta or umbilical cord), may
thus offer certain advantages, but, similarly to otherMSC sources,
bear an additional risk of thromboembolic complications
when applied systemically (4). Therefore, the ideal source of
therapeutic MSCs still needs to be defined, and therapeutic
approaches utilizing BMSCs should critically review in vitro
expansion protocols.
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Figure S1 | Morphological heterogeneity in BMSC preparations from individual
adult and elderly donors. Representative bright-field microscopy images (40x
magnification) of n = 21 BMSC preparations at passages 2–3 vs. 5–6, generated
either from adult (n = 9) or elderly donors (n = 12) with typical fibroblast-like
morphology and some minor phenotypic variation being evident in both cohorts.
The BMSCs derived from elderly donors with diabetes mellitus [DIAB; Elderly P6;
e.g., P237, P316, P336, P354, P660, and P777)] in particular appear to show a
trend of deterioration in morphology and slower growth at higher passages, which
also appears to be the case for the one diabetic donor in the adult group (Adult
P6; P276).
Figure S2 | Focused gene-expression profiling of biobanked resting BMSCs from
elderly donors with or without predominantly non-insulin-dependent early-stage
diabetes. (A,B) Principle component analysis (PCA) was employed to study group
separation comparing elderly donors with or without diabetes (n = 6 each), with a
random dot distribution throughout the graph.
Figure S3 | Heterogeneity in osteogenic and adipogenic differentiation potential
for BMSCs from individual donors. (A) Osteogenic differentiation: Alizarin red
staining of BMSC matrix mineralization for individual donors (n = 9 adult vs. n =
12 elderly donors) at passages 3 and 6 upon in vitro osteogenic induction for 14,
18, and 21 days. (B) Adipogenic differentiation: Nile Red staining of lipid-rich
vacuoles for BMSCs from individual donors (n = 9 adult vs. n = 12 elderly donors)
at passages 3 and 6 upon in vitro adipogenic induction for 10 and 14 days. In
general, both adult and elderly BMSCs display a very large time-dependent
heterogeneity in osteogenic and adipogenic differentiation, which makes any
predictions of functional performance difficult.
Figure S4 | ALP-activity during osteogenic differentiation of adult vs. elderly and
non-diabetic vs. diabetic donors. Alkaline phosphatase (ALP) enzyme activity was
assessed upon in vitro osteogenic induction of BMSCs for 0, 5, and 10 days at P3
and P6 either for: (A) Adult vs. elderly donors (n = 9 and n = 12) or (B)
non-diabetic vs. diabetic donors (n = 14 vs. n = 7, respectively). For all
comparisons, ALP activity peaks at day 5, with similar values at P3 and P6. Data
are shown as mean ± SD and statistical evaluation was performed by using a
Student’s t-test or ANOVA followed by post-tests (∗P < 0.05, ∗∗P < 0.01, and
∗∗∗P < 0.001).
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